बीटा
ट्रायल रडार AI
क्लिनिकल ट्रायल NCT06404086 के लिए लॉन्ग कोविड, लॉन्ग कोविड-19, हाइपरसोमनिया, नींद में खलल वर्तमान में भर्ती जारी है। सभी विवरणों के लिए क्लिनिकल ट्रायल रडार कार्ड दृश्य और AI खोज उपकरण देखें, या यहाँ कुछ भी पूछें।
एक परीक्षण फ़िल्टर मानदंडों से मेल खाता है
कार्ड दृश्य
खोज पर वापस जाएँ

RECOVER-SLEEP: Platform Protocol

भर्ती जारी
चिकित्सा परीक्षण का विवरण मुख्य रूप से अंग्रेजी में उपलब्ध है। हालाँकि, ट्रायल रडार AI मदद कर सकता है! बस 'परीक्षण समझाएं' पर क्लिक करें और अपनी चुनी हुई भाषा में परीक्षण की जानकारी देखें और चर्चा करें।
क्लिनिकल परीक्षण NCT06404086 का मुख्य उद्देश्य उपचार का अध्ययन करना है। यह चिकित्सकीय अध्ययन लॉन्ग कोविड, लॉन्ग कोविड-19, हाइपरसोमनिया, नींद में खलल से जुड़ा हुआ है और यह एक चरण II हस्तक्रियात्मक परीक्षण है। परीक्षण वर्तमान में भर्ती जारी चल रहा है। इसकी शुरुआत 31 जुलाई 2024 को हुई थी, और इसमें कुल 1,074 प्रतिभागियों के नामांकन की योजना है। ड्यूक विश्वविद्यालय इस परीक्षण का नेतृत्व कर रहे हैं और इसके 31 दिसंबर 2025 तक पूरा होने की उम्मीद है। ClinicalTrials.gov वेबसाइट पर यह जानकारी 19 अगस्त 2025 को अंतिम बार अपडेट की गई थी।
संक्षिप्त सारांश
The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure that can be shared by multiple interventions and allows comparative analysis across the interventions. For example, objectives, measures, and endpoints are generalized in the platform protocol, but intervention-specific features are detailed in separate appendices.

This platform protocol is a prospective, multi-center, multi-arm, randomized controlled platform trial evaluating potential interventions for PASC-mediated sleep disturbances. The hypothesis is that symptoms of sleep and circadian disorders that emerge in patients with PASC can be improved by phenotype-targeted interventions. Specific sleep and circadian disorders addressed in this protocol include sleep-related daytime impairment (referred to as hypersomnia) and complex PASC-related sleep disturbance (reflecting symptoms of insomnia and sleep-wake rhythm disturbance).

विस्तृत विवरण
Interventions will be added to the platform protocol as appendices. Each appendix will leverage all elements of the platform protocol, with additional elements described in the individual appendix.

After completing Baseline assessments, participants will be randomized to an intervention group, which is based on their sleep phenotype, or into a placebo/control group.

आधिकारिक शीर्षक

RECOVER-SLEEP: A Platform Protocol for Evaluation of Interventions for Sleep Disturbances in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

चिकित्सीय स्थितियाँ
लॉन्ग कोविडलॉन्ग कोविड-19हाइपरसोमनियानींद में खलल
अन्य अध्ययन आईडी
  • Pro00112484
  • OTA-21-015G (अन्य अनुदान/वित्त पोषण संख्या) (NIH Grant to RTI; RTI subcontracting with DCRI)
NCT नंबर
NCT06404086
अध्ययन प्रारंभ तिथि (वास्तविक)
2024-07-31
अंतिम अद्यतन प्रकाशित
2025-08-19
अध्ययन की समाप्ति तिथि (अनुमानित)
2025-12-31
नामांकन (अनुमानित)
1,074
अध्ययन प्रकार
हस्तक्रियात्मक
चरण
चरण II
स्थिति
भर्ती जारी
प्रमुख शब्द
PASC
प्राथमिक उद्देश्य
उपचार
डिज़ाइन आवंटन
यादृच्छिक
हस्तक्षेप मॉडल
समानांतर
अंधकरण
तिहरा अंध
समूह/हस्तक्षेप
प्रतिभागी समूह/हाथहस्तक्षेप/इलाज
अन्यHypersomnia Arm (Appendix A)
This is a double-blind, phase 2, randomized, placebo-controlled interventional trial of a wake-promoting drug (modafinil or solriamfetol) to treat hypersomnia, defined by elevated scores (\> 55) on the PROMIS 8a SRI scale, in participants with PASC. Participants will be randomized to study drug or control. Participants who meet the eligibility criteria for modafinil will receive either active modafinil or modafinil-matched control. If modafinil is contraindicated, participants will be assessed for solriamfetol. If participants are eligible for solriamfetol, they will receive either active solriamfetol or solriamfetol-matched control. If solriamfetol is contraindicated, participants will be excluded from Appendix A. Modafinil and solriamfetol will be analyzed as a single wake-promoting drug condition versus control. The intervention duration will be 10 weeks. Anticipated enrollment is 474 participants. Details about the Hypersomnia Appendix are available under NCT06404099.
Modafinil
Modafinil is used off-label based on supporting published evidence in major depressive disorder (antidepressant augmentation), multiple sclerosis-related fatigue, Parkinson disease-related excessive daytime sleepiness, and severe cancer-related fatigue (in patients receiving active treatment). Doses up to 400 mg/day, given as a singleMode dose, have been well tolerated, but there is no consistent evidence that this dose confers additional benefit beyond that of the 200 mg dose. Study drug administration will total 10 weeks.
Modafinil Placebo
The placebo will be tooled to look similar to the modafinil tablet, but it will not contain the active ingredient. Modafinil placebo dosing will follow the same titration scheme as modafinil treatment. Unblinded study personnel will manage modafinil and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators.
Solriamfetol
The proposed doses and the schedule of dose escalation are consistent with currently approved FDA labeling for solriamfetol for other disorders of excessive daytime sleepiness. Solriamfetol dosing will total 10 weeks, including 3 weeks for titration and 7 weeks of maintenance. Solriamfetol will be given as a 75 mg tablet (1 or 2 per day) in the morning. The 3-week titration will be facilitated by phone calls between the study team and participants. Titrations in dose will be dependent upon participants' symptoms and tolerance to solriamfetol, with a goal of participants taking the highest dose permitted by symptoms. This dose will be used for the maintenance phase.
Solriamfetol Placebo
The placebo tablet will be tooled to look similar to the solriamfetol tablet, but it will not contain the active ingredient. Solriamfetol placebo dosing will follow the solriamfetol dosing scheme and goal. Unblinded study personnel will manage solriamfetol and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators.
अन्यComplex PASC related Sleep Disturbances (CPSD) Arm (Appendix B )
This is a double-blind, phase 2, randomized, placebo-controlled, interventional trial that combines brief education and a tailored sleep timing prescription for CPSD with therapies that modify circadian timing for participants who report poor sleep quality or daytime sleep-related impairment, defined by elevated scores (≥55) on the PROMIS 8b SD scale, in participants with symptoms that occurred or worsened after COVID-19 infection. Interventions involve tailored lighting (TL) and melatonin. Participants will be randomly assigned to 1 of 4 groups: (a) active TL + oral melatonin, (b) active TL + placebo melatonin, (c) placebo TL + oral melatonin, and (d) placebo TL + placebo melatonin. All groups will receive BBT-CPSD. It is a 2x2 factorial design schema. The intervention duration will be 8 weeks. Anticipated enrollment for this appendix is 600 participants. Additional details about the CPSD Appendix are available under NCT06404112.
मेलाटोनिन
Melatonin dosing will be one tablet of 3 mg immediate release daily consumed 2 hours before the participant's desired bedtime, which is defined as the time at which the participant tries to fall asleep.
Melantonin Placebo
Melatonin placebo dosing will be one placebo tablet once daily consumed 2 hours before the participant's desired bedtime.
Tailored Lighting (TL) Active
TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.
Tailored Lighting (TL) Placebo
TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.
प्राथमिक परिणाम माप
परिणाम मापमाप विवरणसमय सीमा
Total number of participants enrolled in each Appendix
Total number of participants enrolled in each Appendix will be reported. Appendix-specific outcome measure data will be reported under the associated NCT#.
12 months
पात्रता मानदंड

अध्ययन के लिए पात्र आयु
वयस्क, वृद्ध वयस्क
अध्ययन के लिए न्यूनतम आयु
18 Years
अध्ययन के लिए पात्र लिंग
सभी

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  1. ≥ 18 years of age at the time of enrollment

  2. Previous suspected, probable, or confirmed SARS-CoV-2 infection, as defined by the Pan American Health Organization:

    Suspected* case of SARS-CoV-2 infection - Three options, A through C:

    A. Met the clinical OR epidemiological criteria:

    1. Clinical criteria: Acute onset of fever AND cough (influenza-like illness) OR Acute onset of ANY THREE OR MORE of the following signs or symptoms: fever, cough, general, weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, nausea, diarrhea, anorexia;
    2. Epidemiological criteria: Contact of a probable or confirmed case or linked to a COVID-19 cluster; or B. Presented with acute respiratory infection with a history of fever or measured fever of ≥ 38°C and cough, with onset within the last 10 days, and required hospitalization; or C. Presented with no clinical signs or symptoms, NOR meeting epidemiologic criteria with a positive professional use or self-test SARS-CoV-2 Antigen-Rapid Diagnostic Test.

    Probable* case of SARS-CoV-2 infection, defined as having met the clinical criteria above AND was a contact of a probable or confirmed case or is linked to a COVID-19 cluster; or

    Confirmed case of SARS-CoV-2 infection - Two options, A through B:

    A. Presented with a positive nucleic acid amplification test, regardless of clinical criteria OR epidemiological criteria; or B. Met clinical criteria AND/OR epidemiological criteria (See suspected case A), with a positive professional use or self-test SARS-CoV-2 Antigen-Rapid Diagnostic Test.

    * Suspected and probable cases will only be allowed if they occurred before May 1, 2021, and will be limited to 10% of the study population. Otherwise, confirmed cases are required.

  3. New/worse sleep problems following a SARS-CoV-2 infection that have persisted for at least 12 weeks and are still present at the time of consent

  4. PROMIS 8a SRI or 8b SD T Score ≥ 55**

    ** Screening with both the PROMIS 8a SRI and 8b SD will occur for the phenotype assessment portion of the protocol.

  5. Willing and able to provide informed consent, complete the surveys and clinical assessments, and return for all of the necessary follow-up visits

  6. Adequate method of birth control for participants of child-bearing potential

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Known active acute SARS-CoV-2 infection ≤ 4 weeks from consent
  2. Known pregnancy, breastfeeding, or contemplating pregnancy during the study period
  3. Untreated sleep apnea (AHI ≥ 15 or severe sleep-related hypoxemia)
  4. Current night or rotating shift work
  5. Known history of narcolepsy prior to SARS-CoV-2 infection
  6. Any non-marijuana illicit drug use within 30 days of informed consent
  7. Known history of severe mental disorder, such as psychotic disorders and bipolar disorder
  8. Current or recent use (within the last 14 days) of study intervention or similar intervention to treat the underlying condition, unless a washout period is permitted per appendix*
  9. Known allergy/sensitivity or any hypersensitivity to components of the study intervention or control*
  10. Known contraindication(s) to study intervention including prohibited concomitant medications and without the ability to safely hold prohibited concomitant medications (see appendices)*
  11. Currently receiving/using intervention from another clinical trial that could impact or mask treatment effect; refer to MOP for details
  12. Any condition that would make the participant, in the opinion of the investigator, unsuitable for the study

(*)If only one study intervention appendix is open at the time of enrollment. If multiple study intervention appendices are open, a participant may be excluded from any study intervention appendix based on contraindications listed in the study intervention appendix, current use of study intervention, or known allergy/sensitivity/hypersensitivity yet remain eligible for the remaining study intervention appendices.

Duke University logoड्यूक विश्वविद्यालय544 सक्रिय क्लिनिकल ट्रायल्स खोजे जाने के लिए
अध्ययन केंद्रीय संपर्क
संपर्क: Jaelyn R Linski, BA, CCRC, 919-668-8060, [email protected]
संपर्क: Barrie L Harper, BSMT (ASCP) PMP, [email protected]
47 1 देशों में अध्ययन स्थल

Arizona

Banner University Medical Center Phoenix, Phoenix, Arizona, 85006, United States
सक्रिय, भर्ती नहीं
University of Arizona Banner Medical Center, Tucson, Arizona, 85719, United States
Heidi Erickson, संपर्क, 520-626-5287, [email protected]
Parthasarathy Sairam, MD, मुख्य अन्वेषक
भर्ती जारी
The Southern Arizona VA Health Care System, Tucson, Arizona, 85723, United States
Adnan Abbasi, MD, संपर्क
Adnan Abbasi, मुख्य अन्वेषक
भर्ती जारी

California

Stanford University, Palo Alto, California, 94304, United States
Clete Kushida, MD, संपर्क, 650-723-6601, [email protected]
Clete Kushida, MD, मुख्य अन्वेषक
भर्ती जारी
University of California San Francisco General Hospital, San Francisco, California, 94143, United States
Aric Prather, MD, संपर्क
Aric Prather, मुख्य अन्वेषक
Andrew Krystal, उप-अन्‍वेषक
भर्ती जारी

Colorado

University of Colorado Anschutz Medical Campus, Aurora, Colorado, 80045, United States
Sarah Jolley, MD, संपर्क
Sarah Jolley, MD, मुख्य अन्वेषक
Kristine Erlandson, उप-अन्‍वेषक
Neale Lange, उप-अन्‍वेषक
भर्ती जारी
Denver Health and Hospital Authority, Denver, Colorado, 80204, United States
Edward Gardner, MD, संपर्क
Edward Gardner, मुख्य अन्वेषक
भर्ती जारी

District of Columbia

Howard University Hospital, Washington D.C., District of Columbia, 20060, United States
Peter Whitesell, संपर्क
Peter Whitesell, MD, मुख्य अन्वेषक
Zara Martirosyan, उप-अन्‍वेषक
Alem Mehari, उप-अन्‍वेषक
भर्ती जारी

Florida

University of Florida College of Medicine Jacksonville, Jacksonville, Florida, 32209, United States
Carmen Isache, MD, संपर्क
Carmen Isache, MD, मुख्य अन्वेषक
Jorge Verdecia, MD, उप-अन्‍वेषक
भर्ती जारी
Lakeland Regional Medical Center, Lakeland, Florida, 33805, United States
Debra Seoane, MD, संपर्क
Debra Seoane, MD, मुख्य अन्वेषक
भर्ती जारी

Georgia

Grady Memorial Hospital, Atlanta, Georgia, 30303, United States
Jenny Han, MD, संपर्क
Jenny Han, मुख्य अन्वेषक
Tiffany Walker, उप-अन्‍वेषक
भर्ती जारी
Morehouse School of Medicine, Atlanta, Georgia, 30310, United States
Priscilla Igho-Pemu, संपर्क
Priscilla Igho-Pemu, मुख्य अन्वेषक
भर्ती जारी
Emory University, Atlanta, Georgia, 30322, United States
Dayna Johnson, MD, संपर्क, 404-727-8708, [email protected]
Dayna Johnson, MD, मुख्य अन्वेषक
Nancy Collop, MD, उप-अन्‍वेषक
Alex Truong, MD, उप-अन्‍वेषक
भर्ती जारी
Atlanta VA Medical Center, Decatur, Georgia, 30030, United States
Barry Fields, MD, संपर्क
Barry Fields, MD, मुख्य अन्वेषक
भर्ती जारी
Emory Hope Clinic, Decatur, Georgia, 30030, United States
Wiley Zanthia, MD, संपर्क
Wiley Zanthia, मुख्य अन्वेषक
Nadine Rouphael, उप-अन्‍वेषक
Cassie Grimsley-Ackerley, उप-अन्‍वेषक
Kristen Unterberger, उप-अन्‍वेषक
Veronica Smith, उप-अन्‍वेषक
Mary Atha, उप-अन्‍वेषक
Paulina Rebolledo Esteinou, उप-अन्‍वेषक
Kelley Colleen, उप-अन्‍वेषक
Srilatha Edupuganti, उप-अन्‍वेषक
Matthew Collins, उप-अन्‍वेषक
Zanthia Wiley, उप-अन्‍वेषक
Daniel Graciaa, उप-अन्‍वेषक
Jessica Traenkner, उप-अन्‍वेषक
भर्ती जारी

Illinois

Northwestern Memorial Hospital, Chicago, Illinois, 60611, United States
Phyllis Zee, MD, संपर्क
Phyllis Zee, मुख्य अन्वेषक
Kathryn Reid, उप-अन्‍वेषक
Paul Chung, उप-अन्‍वेषक
Alexander Choi, उप-अन्‍वेषक
Lisa Wolfe, उप-अन्‍वेषक
Sabra Abbott, उप-अन्‍वेषक
Mathew Mass, उप-अन्‍वेषक
भर्ती जारी
Cook County Health Specialty Care Center, Chicago, Illinois, 60612, United States
सक्रिय, भर्ती नहीं
Rush University Medical Center, Chicago, Illinois, 60612, United States
James Moy, MD, संपर्क
James Moy, MD, मुख्य अन्वेषक
Babak Mokhlesi, MD, उप-अन्‍वेषक
भर्ती जारी
University of Illinois at Chicago, Chicago, Illinois, 60612, United States
Bharati Prasad, MD, संपर्क
Bharati Prasad, MD, मुख्य अन्वेषक
भर्ती जारी
NorthShore Medical Group, Evanston, Illinois, 60201, United States
Mary Ellen Acree, MD, संपर्क, [email protected]
Amanda Caplan, MD, संपर्क, 1-224-364-2273, [email protected]
Mary Ellen Acree, MD, मुख्य अन्वेषक
Oluwadamilola Adeyemi, MD, उप-अन्‍वेषक
Amanda Caplan, MD, उप-अन्‍वेषक
Michael Glickman, MD, उप-अन्‍वेषक
Benjamin Margolis, MD, उप-अन्‍वेषक
Nicholas Mathenia, MD, उप-अन्‍वेषक
भर्ती जारी
Saint Francis Medical Center, Peoria, Illinois, 61606, United States
Patrick Whitten, MD, संपर्क
Patrick Whitten, मुख्य अन्वेषक
Ossama Ikladios, उप-अन्‍वेषक
Subramanyam Chittivelu, उप-अन्‍वेषक
Kaninika Verma, उप-अन्‍वेषक
भर्ती जारी

Kansas

University of Kansas Medical Center, Kansas City, Kansas, 66160, United States
Damien Stevens, MD, संपर्क
Damien Stevens, मुख्य अन्वेषक
Diego Mazzotti, उप-अन्‍वेषक
भर्ती जारी

Kentucky

University of Kentucky, Lexington, Kentucky, 40536, United States
Christopher Simmons, MD, संपर्क
Christopher Simmons, MD, मुख्य अन्वेषक
Robert Murray, उप-अन्‍वेषक
Sara Pasha, उप-अन्‍वेषक
Sidney Whiteheart, उप-अन्‍वेषक
भर्ती जारी

Maryland

Johns Hopkins Bayview Medical Center, Baltimore, Maryland, 21224, United States
Jonathan Jun, MD, संपर्क, 410-550-0115, [email protected]
Jonathan Jun, MD, मुख्य अन्वेषक
Daisy Duan, MD, उप-अन्‍वेषक
Luu Pham, MD, उप-अन्‍वेषक
भर्ती जारी
Jadestone Clinical Research, LLC, Silver Spring, Maryland, 20904, United States
Jonathan Cohen, MD, संपर्क
Jonathan Cohen, मुख्य अन्वेषक
Homam Ibrahim, उप-अन्‍वेषक
भर्ती जारी

Massachusetts

Tufts Medical Center, Boston, Massachusetts, 02111, United States
Aarti Grover, MD, संपर्क, 617-636-7689, [email protected]
Aarti Grover, MD, मुख्य अन्वेषक
भर्ती जारी
Massachusetts General Hospital, Boston, Massachusetts, 02114, United States
Aleksandar Videnovic, MD, संपर्क, 671-724-3837, [email protected]
Aleksandar Videnovic, MD, मुख्य अन्वेषक
भर्ती जारी
Brigham and Womens Hospital, Boston, Massachusetts, 02115, United States
Daniel Gottlieb, MD, संपर्क
Daniel Gottlieb, MD, मुख्य अन्वेषक
Susan Redline, MD, उप-अन्‍वेषक
भर्ती जारी
Boston Medical Center, Boston, Massachusetts, 02118, United States
Sanford Auerbach, MD, संपर्क
Sanford Auerbach, मुख्य अन्वेषक
Steven Lenio, उप-अन्‍वेषक
भर्ती जारी
Beth Israel Deaconess Med. Ctr., Boston, Massachusetts, 02215, United States
Janet Mullington, MD, संपर्क
Janet Mullington, मुख्य अन्वेषक
Robert Thomas, उप-अन्‍वेषक
भर्ती जारी
University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, 01655, United States
Jennifer Wang, MD, संपर्क
Jennifer Wang, MD, मुख्य अन्वेषक
Evan Bradley, उप-अन्‍वेषक
Mary Co, उप-अन्‍वेषक
भर्ती जारी

New Jersey

Rutgers University - Robert Wood Johnson Medical School, New Brunswick, New Jersey, 08901, United States
Sabiha Hussain, MD, संपर्क
Sabiha Hussain, मुख्य अन्वेषक
Aesha Jobanputra, उप-अन्‍वेषक
भर्ती जारी

New Mexico

University of New Mexico, Albuquerque, New Mexico, 87102, United States
Shanna Diaz, MD, संपर्क, 505-272-2515, [email protected]
Shanna Diaz, MD, मुख्य अन्वेषक
भर्ती जारी

New York

Icahn School of Medicine at Mount Sinai, New York, New York, 10029, United States
Vaishnavi Kundel, MD, संपर्क
Vaishnavi Kundel, MD, मुख्य अन्वेषक
Mira Tadros, उप-अन्‍वेषक
भर्ती जारी

North Carolina

East Carolina University, Greenville, North Carolina, 27834, United States
Paul Bolin, MD, संपर्क
Paul Bolin, MD, मुख्य अन्वेषक
भर्ती जारी

Ohio

University of Cincinnati Medical Center, Cincinnati, Ohio, 45220, United States
Ann Romaker, MD, संपर्क
Ann Romaker, MD, मुख्य अन्वेषक
Rachel Foot, MD, उप-अन्‍वेषक
भर्ती जारी
University Hospitals of Cleveland Medical Center, Cleveland, Ohio, 44106, United States
Kingman Strohl, MD, संपर्क
Kingman Strohl, MD, मुख्य अन्वेषक
Susheel Patil, उप-अन्‍वेषक
भर्ती जारी

Oregon

Oregon Health and Science University, Portland, Oregon, 97239, United States
Hope Aluko, MD, संपर्क
Hope Aluko, मुख्य अन्वेषक
Akram Khan, उप-अन्‍वेषक
Maureen Lyons, उप-अन्‍वेषक
भर्ती जारी

Texas

Southwest Family Medicine Associates, Dallas, Texas, 75235, United States
Chrisette Sharma, MD, संपर्क, 469-893-1242, [email protected]
Chrisette Dharma, MD, मुख्य अन्वेषक
Angela Kemp, MD, उप-अन्‍वेषक
Monica Ramirez, MD, उप-अन्‍वेषक
भर्ती जारी
Houston Methodist Hospital, Houston, Texas, 77030, United States
Eleftherios Mylonakis, MD, संपर्क
Eleftherios Mylonakis, मुख्य अन्वेषक
Rodney Folz, उप-अन्‍वेषक
Deepa Gotur, उप-अन्‍वेषक
Faisal Zahiruddin, उप-अन्‍वेषक
भर्ती जारी
University of Texas Health Science Center at Houston, Houston, Texas, 77030, United States
Reeba Matthew, MD, संपर्क
Reeba Matthew, MD, मुख्य अन्वेषक
Bela Patel, उप-अन्‍वेषक
Ruckshanda Majid, उप-अन्‍वेषक
भर्ती जारी
New Dawn Wellness and Medical Research Center, Houston, Texas, 77082, United States
Adanna Ukazu, MD, संपर्क
Adanna Ukazu, MD, मुख्य अन्वेषक
Kerollos Shaker, MD, उप-अन्‍वेषक
Elaine Shehata, MD, उप-अन्‍वेषक
भर्ती जारी

Virginia

University of Virginia Health System, Charlottesville, Virginia, 22908, United States
Alexandra Kadl, MD, संपर्क
Alexandra Kadl, MD, मुख्य अन्वेषक
Scott Schecter, MD, उप-अन्‍वेषक
Jeffrey Sturek, MD.PhD, उप-अन्‍वेषक
भर्ती जारी

Washington

Evergreen Hospital Medical Center, Kirkland, Washington, 98034, United States
Pinky Agarwal, MD, संपर्क
Pinky Agarwal, MD, मुख्य अन्वेषक
भर्ती जारी

West Virginia

University Physicians and Surgeons (DBA Marshall Health), Huntington, West Virginia, 25701, United States
Imran Khawaja, MD, संपर्क
Imran Khawaja, MD, मुख्य अन्वेषक
भर्ती जारी
West Virginia Clinical and Translational Science Institute, Morgantown, West Virginia, 26506, United States
Sunil Sharma, MD, संपर्क
Sunil Sharma, मुख्य अन्वेषक
Robert Stansbury, उप-अन्‍वेषक
Edward Rojas, उप-अन्‍वेषक
भर्ती जारी

Wisconsin

Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States
Rose Franco, MD, संपर्क, 414-955-7040, [email protected]
Rose Franco, MD, मुख्य अन्वेषक
भर्ती जारी